Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

Mutant RAS has remained recalcitrant to targeted therapy efforts. Here we demonstrate that combined treatment with poly ADP ribose polymerase (PARP) inhibitors and MEK inhibitors evokes unanticipated, synergistic cytotoxic effects in vitro and in vivo in multiple RAS mutant tumor models across tumor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Transl Med
Main Authors: Sun, Chaoyang, Fang, Yong, Yin, Jun, Chen, Jian, Ju, Zhenlin, Zhang, Dong, Chen, Xiaohua, Vellano, Christopher P., Jeong, Kang Jin, Ng, Patrick Kwok-Shing, Eterovic, A. Karina, Bhola, Neil H., Lu, Yiling, Westin, Shannon N, Grandis, Jennifer R., Lin, Shiaw-Yih, Scott, Kenneth L., Peng, Guang, Brugge, Joan, Mills, Gordon B.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5919217/
https://ncbi.nlm.nih.gov/pubmed/28566428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal5148
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares